CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A

Neoplasia

Volumn 9, Issue 6, 2007, Pages 495-503

  Subramanian, Chitra ^a   Jarzembowski, Jason A ^a,c   Opipari Jr , Anthony W ^a   Castle, Valerie P ^a   Kwok, Roland P S ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 6428 Medical Science I ^*  (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bax; Histone acetyltransferase; Histone deacetylase; Ku70

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; KU ANTIGEN; PROTEIN BAX; TRICHOSTATIN A;

ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 34250822248     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07262     Document Type: Article

References (22)

1. Sterner DE and Berger SL (2000). Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64 (2), 435-459.
2. Marks PA, Richon VM, and Rifkind RA (2000). Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (15), 1210-1216.
3. Johnstone RW and Licht JD (2003). Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 (1), 13-18.
4. Subramanian C, Opipari AW Jr, Bian X, Castle VP, and Kwok RP (2005). Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102 (13), 4842-4847.
5. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, and Matsuyama S (2003). Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 5 (4), 320-329.
6. Mimori T, Hardin JA, and Steitz JA (1986). Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem 261 (5), 2274-2278.
7. Rathmell WK and Chu G (1994). Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. Proc Natl Acad Sci USA 91 (16), 7623-7627.
8. Dvir A, Peterson SR, Knuth MW, Lu H, and Dynan WS (1992). Ku autoantigen is the regulatory component of a template-associated protein kinase that phosphorylates RNA polymerase II. Proc Natl Acad Sci USA 89 (24), 11920-11924.
9. Gottlieb TM and Jackson SP (1993). The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 72 (1), 131-142.
10. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM, and Sinclair DA (2004). Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13 (5), 627-638.
11. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, and Sinclair DA (2004). Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305 (5682), 390-392.
12. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, and Fruhwald MC (2007). Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120 (8), 1787-1794.
13. Kwok RP, Liu XT, and Smith GD (2006). Distribution of co-activators CBP and p300 during mouse oocyte and embryo development. Mol Reprod Dev 73 (7), 885-894.
14. Goodman RH and Smolik S (2000). CBP/p300 in cell growth, transformation, and development. Genes Dev 14 (13), 1553-1577.
15. Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, et al. (1995). Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP [see comments]. Nature 376 (6538), 348-351.
16. Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, den Dunnen JT, van Ommen GJ, Breuning MH, et al. (2005). Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet 76 (4), 572-580.
17. Ugai H, Uchida K, Kawasaki H, and Yokoyama KK (1999). The coactivators p300 and CBP have different functions during the differentiation of F9 cells. J Mol Med 77 (6), 481-494.
18. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, and Livingston DM (2002). Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci USA 99 (23), 14789-14794.
19. Valent A, Benard J, Venuat AM, Silva J, Duverger A, Duarte N, Hartmann O, Spengler BA, and Bernheim A (1999). Phenotypic and genotypic diversity of human neuroblastoma studied in three IGR cell line models derived from bone marrow metastases. Cancer Genet Cytogenet 112 (2), 124-129.
20. Mora J, Cheung NK, Juan G, Illei P, Cheung I, Akram M, Chi S, Ladanyi M, Cordon-Cardo C, and Gerald WL (2001). Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res 61 (18), 6892-6898.
21. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, et al. (1999). The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86 (2), 364-372.
22. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JN, and Matthay KK (2001). International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 92 (9), 2451-2461.